Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers

• প্রধান লেখক: Dipesh Tamrakar (Author), Pranodan Poudel (Author), Pragya Thapa (Author), Srijana Singh (Author), Amit Khadgi (Author), Sameera Thapa (Author), Rajendra Tamrakar (Author), Anmol Shrestha (Author), Surendra Madhup (Author), Ganesh Kumar Rai (Author), Birendra Prasad Gupta (Author), Tarun Saluja (Author), Sushant Sahastrabuddhe (Author), Rajeev Shrestha (Author)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

ABSTRACTTyphoid fever is a significant public health concern with most of the sufferers between 15 and 25 y of age in Nepal. We undertook this study to demonstrate Vi polysaccharide conjugated with diphtheria toxoid (Vi-DT) conjugate vaccine which is non-inferior to Typbar typhoid conjugate vaccine,...